The Use of Laparoscopic Transversus Abdominis Plane Block in Gastric Bypass Surgery (LapTAP)

• Status: Unknown status
• Trial end date: 2020-02-01
• Target enrollment: 0
• Participant gender: All

Summary

Randomized, Double-Blinded, Placebo-Controlled Trial of Laparoscopic Transverse Abdominis Plane (Lap TAP) and Rectus Sheath Block in elective Gastric Bypass Surgery aiming to evaluate the benefit of a laparoscopically -guided, surgical transversus abdominis plane (TAP) block and rectus sheath block in reducing post-operative opioid consumption and improving outcomes in patients undergoing laparoscopic gastric bypass surgery. The results of this study will provide further evidence on the optimal means to obtain analgesia in patients undergoing gastric bypass surgery

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ottawa Hospital Research Institute
• Treatments: Ropivacaine

Criteria

Inclusion Criteria:

• Patients undergoing Roux-en-Y gastric bypass surgery;

• Patients who able to tolerate general anesthetic and pneumoperitoneum;

• Patients who able to provide informed consent for the surgery;

• Patients over the age of 18 years;

Exclusion Criteria:

• Patient undergoing planned sleeve gastrectomy (intra-op conversion to sleeve gastrectomy after delivery of Ropivacaine/placebo will be included and analyzed using intention-to-treat approach)

• Patients with an allergy to local anesthetics

• Patients with severe underlying cardiovascular disease (ie: congestive heart failure, conduction abnormalities, and ischemic heart disease)

• Patients with chronic renal disease Stage 3 or greater (Creatinine clearance less than 60mL/min)

• Patients with hepatic dysfunction Child-Pugh Class B or C

• Patients with previous foregut surgery including esophageal, gastric, liver, and pancreas resections

• Patients weighing less than or equal to 100 kilograms as measured in the pre-admission unit

• Patients enrolled in any other study involving involve tissue biopsy.

• Patients with Chronic Pain and Chronic Opioid use- Oral Morphine Equivalent of >100mg/day